UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 15, 2009

 

DRAGON PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

 

 

Florida
(State or Other Jurisdiction of
Incorporation)

 

000-27937
(Commission File Number)

 

65-0142474

(IRS Employer
Identification No.)

 

 

 

 


650 West Georgia Street, Suite 310

Vancouver, British Columbia  

(Address of Principal Executive Offices)


 

 

 

V6B 4N9

(Zip Code)

 

 

(604) 669-8817

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

1

 

Section 2 – Financial Information

 

Item 2.02

Results of Operations and Financial Condition

 

          On August 15, 2009, Dragon Pharmaceutical Inc. (the “Company”) issued a press release announcing its financial results for the three months ending June 30, 2009. A copy of the press release is attached hereto as Exhibit 99.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01

Financial Statements and Exhibits

 

 

Exhibit No.

Exhibit Description

 

 

99

Press release dated August 15, 2009, titled “Dragon Pharma Reports 2009 Second Quarter Financial Results”

 

The information set forth under Item 2.02 of this Form 8-K and Exhibit 99 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, whether made before or after the date hereof and irrespective of any general incorporation by reference language in any filing.

 

Portions of this report constitute “forward-looking statements” defined by federal law. Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov.

 

2                 

 

 

 

SIGNATURE

 

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DRAGON PHARMACEUTICAL INC.,

 

a Florida Corporation

 

 

Dated: August 19, 2009

/s/ Maggie Deng
Maggie Deng

Chief Operating Officer

 

 

 

 

3

 

 

EXHIBIT INDEX

 

 

Exhibit No.

Description

 

 

99

Press release dated August 15, 2009 titled “Dragon Pharma Reports 2009 Second Quarter Financial Results”

 

 

 

 

 

4